EU RESPONSE TO COVID-19
Research & Innovation Projects
RNA based vaccine for coronavirus
In 2014 CureVac received the first ever EU innovation inducement prize of €2 million.
• Testimonial: Lidia Oostvogels (Area head infectious diseases at Curevac)
Sustainable downstream processing of vaccines through incorporation of nanobiotechnologies: higher purity, faster and cheaper with novel affinity ligands and biomimetic membranes. Led by Instituto de Biologia Experimental e Tecnológica – IBET (PT).
The vaccine Alliance of Bill and Melinda Gates Foundation.
Engineering of Mycoplasma pneumoniae as a broad-spectrum animal vaccine.
Rapid therapy development through Open Coronavirus Vaccine Platform.
• Testimonial: Matti Sällberg (Head of Department of Laboratory Medicine, Karolinska Institute, Stockholm)
Breeding new plant biofactories
Genome editing and other new breeding techniques to adapt tobacco plants as biofactories for health-related bioproducts, such as vaccines, and antibodies.
Prevention of 2019 nCoV infection through development and clinical testing of a novel Virus Like Particle (VLP) vaccine to expose coronavirus proteins to the immune system.
• Testimonial from Morten Nielsen (Departement of immunology and microbiology, University of Copenhagen)
• Futuris video: Europe supercharges research in the battle against COVID-19
The EU vaccine R&D infrastructure that offers researchers a wide range of technical vaccine development services at no cost in most cases. Budget: €20.5 million since 2009.